Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE LPF versus RASUVO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE LPF versus RASUVO.
METHOTREXATE LPF vs RASUVO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the synthesis of tetrahydrofolate and subsequently thymidylate and purine synthesis. This inhibits DNA synthesis, repair, and cellular replication. In low-dose regimens, it has anti-inflammatory and immunomodulatory effects through adenosine release and inhibition of cytokine production.
RASUVO is a biosimilar of adalimumab, a recombinant human IgG1 monoclonal antibody that binds specifically to tumor necrosis factor alpha (TNFα) and neutralizes its biological activity by blocking its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecule expression and cytokine release.
7.5 to 25 mg orally once weekly for rheumatoid arthritis; for psoriasis, 10 to 25 mg orally once weekly. Intravenous dosing varies by indication; for high-dose methotrexate (e.g., osteosarcoma), 8 to 12 g/m² IV over 4 hours.
Subcutaneous injection: 200 mg once weekly.
None Documented
None Documented
Terminal half-life 3-10 hours for low doses, 8-15 hours for high doses; prolonged to 12-24 hours in renal impairment due to delayed clearance.
Approximately 11-17 days (mean 13 days); supports every-4-week dosing interval for methotrexate-naive patients and every-4-week or every-2-week dosing in combination with methotrexate.
Primarily renal (80-90% unchanged via glomerular filtration and active tubular secretion); small amount biliary/fecal (<10%).
Primarily cleared via proteolysis; renal and fecal excretion of active drug minimal. No specific biliary or renal excretion as a percentage.
Category D/X
Category C
Antimetabolite
Antimetabolite